FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387206821> ?p ?o ?g. }

• W4387206821 endingPage "e530" @default.
• W4387206821 startingPage "e530" @default.
• W4387206821 abstract "Radiotherapy (RT) improves survival in pediatric diffuse intrinsic pontine glioma (DIPG). After recurrence, re-irradiation (re-RT) offers palliation of symptoms and extends life in patients after exhaustion of investigational options and clinical decline. Practice patterns vary in dose and fractionation for re-RT, with majority of reported cases treated with conventional fractionation. Given radiobiologic rationale for hypofractionation in glioblastoma, we hypothesized that treatment with 3 Gy per fraction is safe and effective for re-RT to the brainstem for DIPG.We identified patients at our institution, ages 1-25, treated with re-RT to the brainstem for DIPG from 2012-2022. Patient demographics, treatment details, and clinical outcomes were reviewed from the medical record. Analysis was completed in R 4.2.2 using Kaplan-Meier method with log-rank test for survival estimates and Fisher's exact test for categorical variables.A total of 22 patients received re-RT for DIPG. All patients had received 54-59.4 Gy with conventional fractionation at the time of diagnosis. Re-RT dose was initially 20-24 Gy in 2-Gy fractions (n = 6) and continued at 30-36 Gy in 3-Gy fractions (n = 14). Two patients did not complete re-RT due to continued clinical decline from disease progression after 1-2 fractions. Of the 20 that completed re-RT, 11 were female, median age was 5 years (3-14), median interval since initial RT was 8 months (3-20), 12 (60%) received concurrent bevacizumab, and OS from diagnosis was 18 months. Median OS from start of re-RT for patients treated with 3 Gy per fraction was 8.2 months and 13 (93%) clinically improved to taper pre-treatment steroid dose down (n = 9) or off (n = 4) within 2 months after re-RT. For those treated with 2 Gy per fraction, median OS from re-RT was 7.5 months and 3 (75%) improved to taper steroids down (n = 2) or off (n = 1). Overall, 2 patients were not on steroids, 2 were maintained at same steroid dose, and 0 required increase from pre-treatment steroid dose within 6 weeks after re-RT. There was no significant difference in OS from re-RT (p = 0.2) or steroid taper (p = 0.4) between fractionation groups. No patients developed radionecrosis of normal brain tissue.Patients receiving re-RT achieved extended survival comparable to published outcomes and majority experienced clinical improvement to allow steroid taper. While radionecrosis is a reported risk in prior published series, our experience demonstrates the safety and effectiveness of using 3 Gy per fraction to 30-36 Gy for meaningful palliation in this population." @default.
• W4387206821 created "2023-09-30" @default.
• W4387206821 creator A5040097148 @default.
• W4387206821 creator A5046103284 @default.
• W4387206821 creator A5058490970 @default.
• W4387206821 creator A5068118481 @default.
• W4387206821 creator A5074725191 @default.
• W4387206821 date "2023-10-01" @default.
• W4387206821 modified "2023-10-17" @default.
• W4387206821 title "Re-Irradiation for Diffuse Intrinsic Pontine Glioma with 3 Gy per Fraction" @default.
• W4387206821 doi "https://doi.org/10.1016/j.ijrobp.2023.06.1811" @default.
• W4387206821 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37785646" @default.
• W4387206821 hasPublicationYear "2023" @default.
• W4387206821 type Work @default.
• W4387206821 citedByCount "0" @default.
• W4387206821 crossrefType "journal-article" @default.
• W4387206821 hasAuthorship W4387206821A5040097148 @default.
• W4387206821 hasAuthorship W4387206821A5046103284 @default.
• W4387206821 hasAuthorship W4387206821A5058490970 @default.
• W4387206821 hasAuthorship W4387206821A5068118481 @default.
• W4387206821 hasAuthorship W4387206821A5074725191 @default.
• W4387206821 hasConcept C126322002 @default.
• W4387206821 hasConcept C155806632 @default.
• W4387206821 hasConcept C2776694085 @default.
• W4387206821 hasConcept C2777802072 @default.
• W4387206821 hasConcept C2778227246 @default.
• W4387206821 hasConcept C2780387249 @default.
• W4387206821 hasConcept C2989005 @default.
• W4387206821 hasConcept C502942594 @default.
• W4387206821 hasConcept C509974204 @default.
• W4387206821 hasConcept C71924100 @default.
• W4387206821 hasConceptScore W4387206821C126322002 @default.
• W4387206821 hasConceptScore W4387206821C155806632 @default.
• W4387206821 hasConceptScore W4387206821C2776694085 @default.
• W4387206821 hasConceptScore W4387206821C2777802072 @default.
• W4387206821 hasConceptScore W4387206821C2778227246 @default.
• W4387206821 hasConceptScore W4387206821C2780387249 @default.
• W4387206821 hasConceptScore W4387206821C2989005 @default.
• W4387206821 hasConceptScore W4387206821C502942594 @default.
• W4387206821 hasConceptScore W4387206821C509974204 @default.
• W4387206821 hasConceptScore W4387206821C71924100 @default.
• W4387206821 hasIssue "2" @default.
• W4387206821 hasLocation W43872068211 @default.
• W4387206821 hasLocation W43872068212 @default.
• W4387206821 hasOpenAccess W4387206821 @default.
• W4387206821 hasPrimaryLocation W43872068211 @default.
• W4387206821 hasRelatedWork W1983863207 @default.
• W4387206821 hasRelatedWork W1994448744 @default.
• W4387206821 hasRelatedWork W2025724318 @default.
• W4387206821 hasRelatedWork W2093044092 @default.
• W4387206821 hasRelatedWork W2786295589 @default.
• W4387206821 hasRelatedWork W2903232234 @default.
• W4387206821 hasRelatedWork W3082730574 @default.
• W4387206821 hasRelatedWork W3214062064 @default.
• W4387206821 hasRelatedWork W4319265242 @default.
• W4387206821 hasRelatedWork W4387206995 @default.
• W4387206821 hasVolume "117" @default.
• W4387206821 isParatext "false" @default.
• W4387206821 isRetracted "false" @default.
• W4387206821 workType "article" @default.